Author： Figueroa II J.E. Vijayagopal P. Prasad C.
Publisher： Elsevier
ISSN： 0006-291X
Source： Biochemical and Biophysical Research Communications, Vol.293, Iss.2, 2002-05, pp. : 847-849
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Azaftig is an urinary proteoglycan present in some cancer and AIDS patients experiencing weight loss. Administration of azaftig to mice results in weight loss that is associated with loss of fat depot. So far, very little is known about the mechanism underlying loss of fat depot in mice or weight loss in patients excreting azaftig. Augmentation of lipolysis may be one mechanism that can cause reduction of fat depot. Therefore, the present study was designed to examine the effect of azaftig on lipolysis by adipocytes derived from obese rats and humans. Results show a dose-dependent potentiation of lipolysis by azaftig in both rat and human adipocytes.
Related content
Access to resources
Recommend
By Yonemitsu Y. Kaneda Y. Komori K. Hirai K. Sugimachi K. Sueishi K.
Biochemical and Biophysical Research Communications, Vol. 231, Iss. 2, 1997-02 ,pp. :
By Müller Günter Wied Susanne Jung Christian Frick Wendelin Biemer-Daub Gabriele
Archives of Physiology and Biochemistry, Vol. 116, Iss. 1, 2010-02 ,pp. :